A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis
IntroductionDupilumab is the first biological treatment for atopic dermatitis (AD). Dupilumab-associated ocular surface disease (DAOSD) is one of the most commonly reported side effects in patients with AD during dupilumab treatment. This study aimed to identify risk factors for DAOSD in a real-worl...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2024-08-01
|
| Seri Bilgileri: | Frontiers in Pharmacology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1425550/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|